Addex receives milestone from Merck & Co
This article was originally published in Scrip
Executive Summary
Addex Pharmaceuticals has received a second milestone worth $500,000 from Merck & Co as part of their collaboration to develop allosteric modulators for the treatment of Parkinson's disease.